DGIdb - SULFASALAZINE Drug Record

SULFASALAZINE CHEMBL421 FDA Approved

Alternate Names:

Salazopyrin-En
Salazopyrin E.C.
Ucine
Sulfasalazine
Colizine
Salicylazosulfapyridine
Salazosulfapyridine
Sulphasalazine
Azulfidine
S.A.S.
Azulfidine EN
Salazopyrin
SAS-500
S.A.S.-500
Azulfidine EN-Tabs
C29469
Sulcolon
Zopyrin
Weiliufen
Sulfasalazine Delayed-release
Sulfacol
Sas Tab 500mg
Sas Enema 3gm/100ml
Salazopyrin Tab 500mg
Salazopyrin Enema 3gm/100ml
Salazopyrin Enema 3.0gm/100ml
Salazopyrin En-tabs 500 mg
Salazopyrin EN-Tabs
Salazopyrin EN
Salazoprin
Salazopirina
Salazine
Salazidin
Salazar
Salasopyrine
Saaz-DS
Saaz
S.A.S. Enteric 500mg
Reumazin
Ratio-sulfasalazine Tab 500mg
Ratio-sulfasalazine En
Pyralin EN
Pleon
PMS-sulfasalazine-E.C. Tab 500mg
PMS-sulfasalazine 500mg/tab USP
Orb-sulfasalazine EC
Lazafin
Lanofen
Iwata
Flogostop
Eminapyrin
Disalazin
Colo-Pleon
Bomecon
Azulfin
Azulfdidina
Asasurfan
Apo Sulfasalazine Tab 500mg
599-79-1
Salazosulfapyridinum
Salazosulfapiridina
Azopyrin
5-(P-(2-Pyridylsulfamyl)phenylazo)salicylic acid
5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid
5-((P-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid
2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
DB00795
W-T SASP ORAL
NCGC00016518-01
BRN 0356241
WLN: T6NJ BSWMR DNUNR DQ CVQ
NSC203730
EINECS 209-974-3
SI-88
HMS1569H21
SALAZOSULFAPIRIDINA [INN-SPANISH]
SALAZOSULFAPYRIDINUM [INN-LATIN]
HSDB 3395
CHEMBL242373
CCRIS 4713
BIDD:GT0161
CAS-599-79-1
SULFASALAZINA [INN-SPANISH]
NCGC00090903-01
AZULFADINE
SULFASALAZINUM [INN-LATIN]
AC1Q72VB
S.A.S. ENTERIC-500
S.A.S. 500
SULFASALAZINE (USP/INN)
AC1NSE0P
PMS-SULFASALAZINE E.C.
13GS
SALAZO-SULFAPYRIDINUM
SULPHASALAZINE, N-
PRESTWICK_848
AZLUFIDINE EN-TABS
AZULFIDINE (TN)
PMS-SULFASALAZINE
ALTI-SULFASALAZINE
UNII-3XC8GUZ6CB
SULFAZALAZINE
AZOSULFIDIN
SALAZOSULFAPYRIDIN
BENZOSULFA
AZOPYRINE
SULFASALAZINUM
SULFASALAZINA
SALAZOPYRIDIN
SALAZOPIRIDAZIN
5359476
SULFASALAZIN
SALISULF
REUPIRIN
2-?HYDROXY-?5-?[2-?[4-?[(2-?PYRIDINYLAMINO)SULFONYL]PHENYL]DIAZENYL]-?BENZOIC ACID
(3Z)-6-OXO-3-(2-{4-[(PYRIDIN-2-YL)SULFAMOYL]PHENYL}HYDRAZIN-1-YLIDENE)CYCLOHEXA-1,4-DIENE-1-CARBOXYLIC ACID
(3E)-6-OXO-3-[[4-(PYRIDIN-2-YLSULFAMOYL)PHENYL]HYDRAZINYLIDENE]CYCLOHEXA-1,4-DIENE-1-CARBOXYLIC ACID
(3E)-6-OXO-3-[[4-(2-PYRIDYLSULFAMOYL)PHENYL]HYDRAZONO]CYCLOHEXA-1,4-DIENE-1-CARBOXYLIC ACID
2-HYDROXY-5-((4-[(2-PYRIDINYLAMINO)SULFONYL]PHENYL)DIAZENYL)BENZOIC ACID #
2-HYDROXY-5-[(E)-[4-(2-PYRIDYLSULFAMOYL)PHENYL]AZO]BENZOIC ACID
SULPHASALAZINE, ANTIBIOTIC FOR CULTURE MEDIA USE ONLY
5-[[4-(2-PYRIDYLSULFAMOYL)PHENYL]AZO]SALICYLIC ACID
Q-201769
3B2-0009
AB00052101-06
AB00052101-04
J10488
AB0013330
HY-14655
HE270326
H881
DR002328
AK163126
NSC-757330
NSC-667219
NC00237
MCULE-7533021815
HS-0062
CS-2145
CCG-100987
AN-8097
ZINC14768602
NSC757330
DL-510
CCG-39145
PHARMAKON1600-01500552
HMS2232H07
HMS2096H21
NCEXYHBECQHGNR-QZQOTICOSA-N
BENZOIC ACID, 2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)-
2-HYDROXY-5-({4-[(2-PYRIDYLAMINO)SULFONYL]PHENYL}DIAZENYL)BENZOIC ACID
CHEMBL100848
SCHEMBL18490
5-[4-(2-PYRIDYLSULFAMOYL)-PHENYLAZO]-SALICYLIC ACID
TL8003811
SMR000059146
AC-20497
SMP2_000059
IDI1_000860
NSC 203730
DB08518
BENZOIC ACID, 2-HYDROXY-5-[[4-[(2-PYRIDINYLAMINO)SULFONYL]PHENYL]AZO]-
AKOS002311709
HMS2092K07
HMS2090P13
HMS2051J21
6-OXO-3-[[4-(PYRIDIN-2-YLSULFAMOYL)PHENYL]HYDRAZINYLIDENE]CYCLOHEXA-1,4-DIENE-1-CARBOXYLIC ACID
2-HYDROXY-5-[(E)-2-{4-[(PYRIDIN-2-YL)SULFAMOYL]PHENYL}DIAZEN-1-YL]BENZOIC ACID
(E)-2-HYDROXY-5-((4-(N-(PYRIDIN-2-YL)SULFAMOYL)PHENYL)DIAZENYL)BENZOIC ACID
F2173-1125
SMR004703430
KB-79573
HE066686
NCGC00186644-01
NCGC00090903-09
ZINC100031653
AKOS025116975
ANW-43676
ZINC3831490
HMS3393J21
HMS3370D16
NCEXYHBECQHGNR-UHFFFAOYSA-N
CTK8B4012
CHEMBL3186737
2-HYDROXY-5-[[4-[(2-PYRIDINYLAMINO)SULFONYL]PHENYL]AZO]BENZOIC ACID
GTPL4840
MLS006011702
SCHEMBL4514
EPITOPE ID:122672
SALAZOPYRIDINREG
SALAZOPYRINREG
AZULFIDINEREG
SSZ
SULFASALAZINE-D4
SBB058178
5384001
(Z)-6-OXO-3-(2-(4-(N-(PYRIDIN-2-YL)SULFAMOYL)PHENYL)HYDRAZONO)CYCLOHEXA-1,4-DIENE-1-CARBOXYLIC ACID
4-(PYRIDYL-2-AMIDOSULFONYL)-3''-CARBOXY-4''-HYDROXYAZOBENZENE
FT-0603483
TR-020767
AB2000147
NCGC00258791-01
NCGC00254313-01
NCGC00090903-11
NCGC00090903-07
NCGC00090903-06
VA11798
NSC-203730
CID5384001
CID5353980
ZINC100030102
TOX21_111037_1
KM0360
DCL001005
DAP000153
BDBM50097125
TOX21_300541
TOX21_201239
TOX21_111037
AZULFIDINE;SALAZOPYRIN;SULPHASALAZINE
CHEBI:489907
CHEBI:45504
SCHEMBL10289061
2-HYDROXY-5-(4-[(PYRIDIN-2-YLAMINO)SULFONYL]PHENYL}DIAZENYL)BENZOIC ACID
SCHEMBL1229516
SCHEMBL1079598
D012460
SALAZOSULFAPYRIDINE (JP16)
SALAZOSULFAPYRIDINE (JP15)
SCHEMBL4515
5-(PARA-(2-PYRIDYLSULFAMOYL)PHENYLAZO)SALICYLIC ACID
HE307458
3XC8GUZ6CB
SANOFI SYNTHELABO BRAND OF SULFASALAZINE
NCHEMBIO.212-COMP9
CID5359476
HENNING BERLIN BRAND OF SULFASALAZINE
RATIOPHARM BRAND OF SULFASALAZINE
ALPHAPHARM BRAND OF SULFASALAZINE
ASHBOURNE BRAND OF SULFASALAZINE
PFIZER BRAND OF SULFASALAZINE
LS-46
SULFASALIZINE
MEDAC BRAND OF SULFASALAZINE
HEYL BRAND OF SULFASALAZINE
FNA BRAND OF SULFASALAZINE
SULFASALAZINE PFIZER BRAND
5-[[P-(2-PYRIDYLSULFAMOYL)PHENYL]AZO]SALICYLIC ACID
5-[4-(2-PYRIDYLSULFAMOYL)PHENYLAZO]SALICYLIC ACID
SULFASALAZINE [USAN:INN]
(3Z)-6-OXO-3-[[4-(PYRIDIN-2-YLSULFAMOYL)PHENYL]HYDRAZINYLIDENE]CYCLOHEXA-1,4-DIENE-1-CARBOXYLIC ACID
RATIO-SULFASALAZINE
RATIO SULFASALAZINE
AC1NTMDP
2-HYDROXY-5-[(E)-{4-[(PYRIDIN-2-YLAMINO)SULFONYL]PHENYL}DIAZENYL]BENZOIC ACID
SULFASALAZINE FNA
SULFASALAZIN MEDAC
EN, AZULFIDINE
SULFASALAZIN-HEYL
SULFASALAZIN HEYL
SALAZOPYRIN EN-TABS
COLO PLEON
ULCOL
SALICYLIC ACID, 5-[[P-(2-PYRIDYLSULFAMOYL)PHENYL]AZO]-
SALICYLIC ACID, 5-((P-(2-PYRIDYLSULFAMOYL)PHENYL)AZO)-
I06-0676
BRD-K10670311-001-06-4
5-(P-(2-PYRIDINYLSULFAMOYL)PHENYLAZO)SALICYLIC ACID
5-22-08-00433 (BEILSTEIN HANDBOOK REFERENCE)
5-[P-(2-PYRIDYLSULFAMOYL)PHENYLAZO]SALICYLIC ACID
DSSTOX_GSID_21256
5-[P-(2-PYRIDYLSULFAMYL)PHENYLAZO]SALICYLIC ACID
DSSTOX_RID_76043
D00448
C07316
2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID
DSSTOX_CID_1256
2-HYDROXY-5-{[4-(PYRIDIN-2-YLSULFAMOYL)PHENYL]DIAZENYL}BENZOIC ACID
S0580
SAM001246530
CPD000059146
NCGC00090903-05
NCGC00090903-04
NCGC00090903-03
NCGC00090903-02
HMS1921C05
NINDS_000860
MOLPORT-003-986-992
MOLPORT-001-792-507
CMAP_000018
KBIO3_002794
KBIO3_002108
KBIO2_007450
KBIO2_006614
KBIO2_004882
KBIO2_004046
KBIO2_002314
KBIO2_001478
KBIO1_000860
HMS502K22
C18H14N4O5S
CHEBI:9334
BPBIO1_000527
SPBIO_002400
SPBIO_001032
SPECTRUM1500552
DIVK1C_000860
MLS001424109
MLS000759399
KBIOSS_002316
KBIOSS_001478
KBIOGR_002314
KBIOGR_000753
BSPBIO_002888
BSPBIO_000479
SPECTRUM5_001443
SPECTRUM4_000347
SPECTRUM3_001364
SPECTRUM2_001216
PRESTWICK3_000520
PRESTWICK2_000520
PRESTWICK1_000520
PRESTWICK0_000520
AC1NS4RK
SPECTRUM_000998
NSC 667219
SASP
ST50767935
NSC667219
ACCUCOL
ASULFIDINE
5353980
48425604
9524
46505451
C1CCNC(C1)NS(=O)(=O)C2CCC(CC2)N=NC3CCC(C(C3)C(=O)O)O
0013-0102-01
PA451547
SAS
RORASUL
685933
4510284
9334
178101542
4840
BAY-299
1346606-50-5
2-HYDROXY-5-[[4-[(2-PYRIDINYLAMINO-D4)SULFONYL]PHENYL]AZO]BENZOIC ACID
5-[[P-(2-PYRIDYLSULFAMOYL-D4)PHENYL]AZO]SALICYLIC ACID
5-[P-(2-PYRIDYLSULFAMYL-D4)PHENYLAZO]SALICYLIC ACID
SALICYLAZOSULFAPYRIDINE-D4
SALAZOSULFAPYRIDINE-D4
SALAZOSULFAPYRIDIN-D4
AZULFIDINE EN-D4
COLO-PLEON-D4
SULPHASALAZINE-D4
SALISULF-D4
REUPIRIN-D4
AZOPYRIN-D4
SALAZOPYRIDIN-D4
AZOPYRINE-D4
BENZOSULFA-D4
AZULFIDINE-D4
SALAZOPYRIN-D4
SULFASALAZIN-D4
SALAZOPYRINE-D4
71752289

Drug Info:

Drug Categories	therapeutic uses
Drug Categories	sulfur compounds
Drug Categories	sulfones
Drug Categories	sulfonamides
Drug Categories	sensory system agents
Drug Categories	physiological effects of drugs
Drug Categories	pharmacologic actions
Drug Categories	peripheral nervous system agents
Drug Categories	organic chemicals
Drug Categories	intestinal antiinflammatory agents
Drug Categories	inorganic chemicals
Drug Categories	gastrointestinal agents
Drug Categories	chemical actions and uses
Drug Categories	central nervous system agents
Drug Categories	bcrp/abcg2 substrates
Drug Categories	bcrp/abcg2 inhibitors
Drug Categories	antirheumatic agents
Drug Categories	antidiarrheals, intestinal antiinflammatory/antiinfective agents
Drug Categories	anti-inflammatory agents, non-steroidal
Drug Categories	anti-inflammatory agents
Drug Categories	anti-infective agents
Drug Categories	analgesics, non-narcotic
Drug Categories	analgesics
Drug Categories	aminosalicylic acid and similar agents
Drug Categories	amides
Drug Categories	alimentary tract and metabolism
Drug Groups	approved
Drug Type	small molecule
Year of Approval	1950
Drug Class	anti-inflammatory agents, non-steroidal
Drug Class	antirheumatic agents
ATC	a07ec(aminosalicylic acid and similar agents)
Drug Type	drug/small molecule
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiinflammatory agent,DMARD

(9 More Sources)

Publications:

Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.
Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.
Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.
Cipolla et al., 2002, Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives., Pharmacol. Res.
Pruzanski et al., 1997, Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity., Biochem. Pharmacol.
Generini et al., Therapy of spondylarthropathy in inflammatory bowel disease., Clin. Exp. Rheumatol.
Mifflin et al., 2004, Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts., Mol. Pharmacol.
Distrutti et al., 2006, 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity., J. Pharmacol. Exp. Ther.
Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.
Schwab et al., 2008, PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells., Carcinogenesis
Desreumaux et al., 2006, Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence., Aliment. Pharmacol. Ther.
Linard et al., 2008, Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist., J. Pharmacol. Exp. Ther.
Rousseaux et al., 2005, Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma., J. Exp. Med.
Weber et al., 2000, Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta., Gastroenterology
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Gout et al., 2001, Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug., Leukemia
Faison et al., 1992, Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase., Prostaglandins
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Stenson et al., 1983, Inhibition of platelet thromboxane synthetase by sulfasalazine., Biochem. Pharmacol.
Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.
Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.
Morabito et al., 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides., J. Clin. Invest.
de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.

SULFASALAZINE PTGS1

Interaction Types:

inhibitor

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

Publications:

Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.
SULFASALAZINE BRD1

Interaction Types:

inhibitor

Interaction Info:

Details of the Assay for Interaction In a <i>BROMOscan®</i> assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:
SULFASALAZINE TAF1

Interaction Types:

inhibitor

Interaction Info:

Details of the Assay for Interaction In a <i>BROMOscan®</i> assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

SULFASALAZINE ALOX5

Interaction Types:

inhibitor

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Publications:

Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.

Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.

Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.

SULFASALAZINE PTGS2

Interaction Types:

inhibitor

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

Publications:

Cipolla et al., 2002, Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives., Pharmacol. Res.

Pruzanski et al., 1997, Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity., Biochem. Pharmacol.

Generini et al., Therapy of spondylarthropathy in inflammatory bowel disease., Clin. Exp. Rheumatol.

SULFASALAZINE PPARG

Interaction Types:

agonist

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Publications:

Schwab et al., 2008, PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells., Carcinogenesis

Desreumaux et al., 2006, Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence., Aliment. Pharmacol. Ther.

Linard et al., 2008, Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist., J. Pharmacol. Exp. Ther.

SULFASALAZINE CHUK

Interaction Types:

inhibitor

Interaction Info:

Publications:

Weber et al., 2000, Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta., Gastroenterology

Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.

SULFASALAZINE IKBKB

Interaction Types:

inhibitor

Interaction Info:

Publications:

Weber et al., 2000, Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta., Gastroenterology

Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.

SULFASALAZINE SLC7A11

Interaction Types:

inhibitor

Interaction Info:

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Gout et al., 2001, Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug., Leukemia

SULFASALAZINE ACAT1

Interaction Types:

inhibitor

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Publications:

Faison et al., 1992, Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase., Prostaglandins

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

SULFASALAZINE TBXAS1

Interaction Types:

antagonist

Interaction Info:

Publications:

Stenson et al., 1983, Inhibition of platelet thromboxane synthetase by sulfasalazine., Biochem. Pharmacol.

SULFASALAZINE PLA2G1B

Interaction Types:

antagonist

Interaction Info:

Publications:

Pruzanski et al., 1997, Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity., Biochem. Pharmacol.

SULFASALAZINE NFKB2

Interaction Types:

activator

Interaction Info:

Publications:
SULFASALAZINE CD83

Interaction Types:

n/a

Interaction Info:

Publications:

Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.
SULFASALAZINE DHFR

Interaction Types:

n/a

Interaction Info:

Publications:

Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.
SULFASALAZINE NT5E

Interaction Types:

n/a

Interaction Info:

Publications:

Morabito et al., 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides., J. Clin. Invest.

SULFASALAZINE TYMP

Interaction Types:

n/a

Interaction Info:

Publications:

de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.

SULFASALAZINE G6PD

Interaction Types:

n/a

Interaction Info:

Publications:
SULFASALAZINE ENOSF1

Interaction Types:

n/a

Interaction Info:

Publications:
SULFASALAZINE TYMSOS

Interaction Types:

n/a

Interaction Info:

Publications:
SULFASALAZINE SLC19A1

Interaction Types:

n/a

Interaction Info:

Publications:
SULFASALAZINE TYMS

Interaction Types:

n/a

Interaction Info:

Publications:
SULFASALAZINE MTR

Interaction Types:

n/a

Interaction Info:

Publications:

DrugBank: DB00795

Version: 5.0.8

Alternate Names:

SULFASALAZINE DrugBank Drug Name

2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid Drug Synonym

2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid Drug Synonym

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories alimentary tract and metabolism

Publications:

Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.

Faison et al., 1992, Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase., Prostaglandins

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

TEND: SULFASALAZINE
- Version: 01-August-2011
Alternate Names:

SULFASALAZINE Primary Drug Name

Drug Info:

Drug Class anti-inflammatory agents, non-steroidal

Year of Approval 1950

Drug Class antirheumatic agents

Publications:
PharmGKB: PA451547
- Version: 12-July-2012
Alternate Names:

SALAZOPIRIDAZIN Drug Trade Name

SALAZOPYRIDIN Drug Trade Name

SALICYLAZOSULFAPYRIDINE Drug Trade Name

Drug Info:

Drug Type drug/small molecule

ATC a07ec(aminosalicylic acid and similar agents)

Publications:
TdgClinicalTrial: SULFASALAZINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: SULFASALAZINE

Version: 14-September-2017

Alternate Names:

C29469 NCI drug code

Drug Info:

Publications:

Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.

Morabito et al., 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides., J. Clin. Invest.

Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.

PubChem: SULFASALAZINE-D4
- Version: 09-Feb-2016
Alternate Names:

SULFASALAZINE-D4 pubchem_primary_name

71752289 PubChem CID

SALAZOPYRINE-D4 Drug Synonym

Drug Info:

Publications:
PubChem: SULFASALAZINE
- Version: 09-Feb-2016
Alternate Names:

SULFASALAZINE pubchem_primary_name

5353980 PubChem CID

SULPHASALAZINE Drug Synonym

Drug Info:

Publications:
GuideToPharmacologyInteractions: 9524
- Version: 27-September-2017
Alternate Names:

BAY-299 GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: DAP000153
- Version: 4.3.02 (25-August-2011)
Alternate Names:

HMS502K22 Drug Synonym

KBIO3_002794 Drug Synonym

599-79-1 CAS Number

Drug Info:

Publications:
TTD: DCL001005
- Version: 4.3.02 (25-August-2011)
Alternate Names:

5359476 Pubchem CId

48425604 Pubchem SId

SULFASALIZINE Primary Drug Name

Drug Info:

Publications:
GuideToPharmacologyInteractions: 4840
- Version: 27-September-2017
Alternate Names:

SULFASALAZINE GuideToPharmacology Ligand Name

178101542 PubChem Drug SID

Drug Info:

Publications:
FDA: Sulfasalazine
- Version: 15-September-2017
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL421
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	sulfasalazine,Azulfidine, Salazopyrin
Novel drug target	Established target
Mechanism of Interaction	Cyclooxygenase inhibitor

Details of the Assay for Interaction	In a <i>BROMOscan®</i> assay.
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Mechanism of Interaction	Arachidonate 5-lipoxygenase inhibitor
Direct Interaction	yes

SULFASALAZINE	DrugBank Drug Name
2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid	Drug Synonym
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid	Drug Synonym

SALAZOPIRIDAZIN	Drug Trade Name
SALAZOPYRIDIN	Drug Trade Name
SALICYLAZOSULFAPYRIDINE	Drug Trade Name

SULFASALAZINE-D4	pubchem_primary_name
71752289	PubChem CID
SALAZOPYRINE-D4	Drug Synonym

SULFASALAZINE	GuideToPharmacology Ligand Name
178101542	PubChem Drug SID

SULFASALAZINE Drug Record

SULFASALAZINE CHEMBL421 FDA Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types: inhibitor

Interaction Info: Trial Name sulfasalazine,Azulfidine, Salazopyrin Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

Publications: Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.

Interaction Types: inhibitor

Interaction Info: Details of the Assay for Interaction In a <i>BROMOscan&reg;</i> assay. Specific Action of the Ligand Inhibition Endogenous Drug? False

Publications:

Interaction Types: inhibitor

Interaction Info: Details of the Assay for Interaction In a <i>BROMOscan&reg;</i> assay. Specific Action of the Ligand Inhibition Endogenous Drug? False

Publications:

Interaction Types: inhibitor

Interaction Info: Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor Direct Interaction yes

Interaction Types: inhibitor

Interaction Info: Trial Name sulfasalazine,Azulfidine, Salazopyrin Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

Interaction Types: agonist

Interaction Info: Trial Name sulfasalazine,Azulfidine, Salazopyrin Novel drug target Established target

Interaction Types: inhibitor

Interaction Info:

Interaction Types: inhibitor

Interaction Info:

Interaction Types: inhibitor

Interaction Info:

Publications: Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res. Gout et al., 2001, Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug., Leukemia

Interaction Types: inhibitor

Interaction Info: Trial Name sulfasalazine,Azulfidine, Salazopyrin Novel drug target Established target

Publications: Faison et al., 1992, Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase., Prostaglandins Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

Interaction Types: antagonist

Interaction Info:

Publications: Stenson et al., 1983, Inhibition of platelet thromboxane synthetase by sulfasalazine., Biochem. Pharmacol.

Interaction Types: antagonist

Interaction Info:

Publications: Pruzanski et al., 1997, Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity., Biochem. Pharmacol.

Interaction Types: activator

Interaction Info:

Publications:

Interaction Types: n/a

Interaction Info:

Publications: Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.

Interaction Types: n/a

Interaction Info:

Publications: Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.

Interaction Types: n/a

Interaction Info:

Publications: Morabito et al., 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides., J. Clin. Invest.

Interaction Types: n/a

Interaction Info:

Publications: de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.

Interaction Types: n/a

Interaction Info:

Publications:

Interaction Types: n/a

Interaction Info:

Publications:

Interaction Types: n/a

Interaction Info:

Publications:

Interaction Types: n/a

Interaction Info:

Publications:

Interaction Types: n/a

Interaction Info:

Publications:

Interaction Types: n/a

Interaction Info:

Publications:

DrugBank: DB00795

Alternate Names: SULFASALAZINE DrugBank Drug Name 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid Drug Synonym 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid Drug Synonym

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories alimentary tract and metabolism

TEND: SULFASALAZINE

Alternate Names: SULFASALAZINE Primary Drug Name

Drug Info: Drug Class anti-inflammatory agents, non-steroidal Year of Approval 1950 Drug Class antirheumatic agents

Publications:

PharmGKB: PA451547

Alternate Names: SALAZOPIRIDAZIN Drug Trade Name SALAZOPYRIDIN Drug Trade Name SALICYLAZOSULFAPYRIDINE Drug Trade Name

Drug Info: Drug Type drug/small molecule ATC a07ec(aminosalicylic acid and similar agents)

Publications:

Interaction Types:

inhibitor

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

Publications:

Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.

Interaction Types:

inhibitor

Interaction Info:

Details of the Assay for Interaction In a <i>BROMOscan®</i> assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Interaction Types:

inhibitor

Interaction Info:

Details of the Assay for Interaction In a <i>BROMOscan®</i> assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Interaction Types:

inhibitor

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Interaction Types:

inhibitor

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

Interaction Types:

agonist

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Interaction Types:

inhibitor

Interaction Types:

inhibitor

Interaction Types:

inhibitor

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Gout et al., 2001, Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug., Leukemia

Interaction Types:

inhibitor

Interaction Info:

Trial Name sulfasalazine,Azulfidine, Salazopyrin

Novel drug target Established target

Interaction Types:

antagonist

Publications:

Stenson et al., 1983, Inhibition of platelet thromboxane synthetase by sulfasalazine., Biochem. Pharmacol.

Interaction Types:

antagonist

Publications:

Pruzanski et al., 1997, Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity., Biochem. Pharmacol.

Interaction Types:

activator

Interaction Types:

n/a

Publications:

Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.

Interaction Types:

n/a

Publications:

Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.

Interaction Types:

n/a

Publications:

Morabito et al., 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides., J. Clin. Invest.

Interaction Types:

n/a

Publications:

de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.

Interaction Types:

n/a

Interaction Types:

n/a

Interaction Types:

n/a

Interaction Types:

n/a

Interaction Types:

n/a

Interaction Types:

n/a

Alternate Names:

SULFASALAZINE DrugBank Drug Name

2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid Drug Synonym

2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid Drug Synonym

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories alimentary tract and metabolism

Alternate Names:

SULFASALAZINE Primary Drug Name

Drug Info:

Drug Class anti-inflammatory agents, non-steroidal

Year of Approval 1950

Drug Class antirheumatic agents

Alternate Names:

SALAZOPIRIDAZIN Drug Trade Name

SALAZOPYRIDIN Drug Trade Name

SALICYLAZOSULFAPYRIDINE Drug Trade Name

Drug Info:

Drug Type drug/small molecule

ATC a07ec(aminosalicylic acid and similar agents)

Drug Info:

Drug Indications antiinflammatory agent,DMARD

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C29469 NCI drug code

Alternate Names:

SULFASALAZINE-D4 pubchem_primary_name

71752289 PubChem CID

SALAZOPYRINE-D4 Drug Synonym

Alternate Names:

SULFASALAZINE pubchem_primary_name

5353980 PubChem CID

SULPHASALAZINE Drug Synonym

Alternate Names:

BAY-299 GuideToPharmacology Ligand Name

Alternate Names:

HMS502K22 Drug Synonym

KBIO3_002794 Drug Synonym

599-79-1 CAS Number

Alternate Names:

5359476 Pubchem CId

48425604 Pubchem SId

SULFASALIZINE Primary Drug Name

Alternate Names:

SULFASALAZINE GuideToPharmacology Ligand Name

178101542 PubChem Drug SID